Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Xylometazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 7/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 6/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 6/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.97 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 12/20 | 0.97 |
| ▸ | HTR1B | P28222 | 10/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylometazoline SCHEMBL6436975 | 0.98 | HTR1A (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL34087 | 0.98 | HTR1D (1.00) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3300993 | 0.97 | HTR1D (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3299510 | 0.97 | HTR1D (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL871223 | 0.97 | HTR1D (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3297417 | 0.97 | HTR1D (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Hydrochloric Acid SCHEMBL8153310 | 0.91 | HTR1D (0.97) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3300203 | 0.90 | HTR1D (0.84) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3301402 | 0.90 | HTR1D (0.84) | HTR1ACYP3A4BLMPMP22POLB | |
| Xylometazoline SCHEMBL3304354 | 0.90 | HTR1D (0.84) | HTR1ACYP3A4BLMPMP22POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2909 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4404916-B1 | AN IMPROVED PHARMACEUTICAL COMPOSITION FOR NASAL USE, PREPARATION, AND USE THEREOF | JADRAN GALENSKI LABORATORIJ D D (HR) | 2025-08-06 | — | — | EP | claimed |
| EP-4410369-A2 | COMPOSITION FOR NASAL APPLICATION WITH IMPROVED STABILITY | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH (DE) | 2024-08-07 | — | — | EP | claimed |
| EP-4404916-A1 | AN IMPROVED PHARMACEUTICAL COMPOSITION FOR NASAL USE, PREPARATION, AND USE THEREOF | JADRAN - GALENSKI LABORATORIJ d.d. (HR) | 2024-07-31 | — | — | EP | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| CN-117159467-A | Xylometazoline hydrochloride nasal spray and preparation method thereof | 万全万特制药（厦门）有限公司 | 2023-12-05 | — | — | CN | claimed |
| WO-2023172148-A1 | MEDICATION | AFT PHARMACEUTICALS LTD (NZ) | 2023-09-14 | — | — | WO | claimed |
| WO-2023144614-A1 | NASAL COMPOSITIONS AND METHODS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-08-03 | — | — | WO | claimed |
| US-20230111350-A1 | Opthalmic Compositions for Treating Coronaviruses | ZEBRA BIOTECH PTY LTD (AU) | 2023-04-13 | — | — | US | claimed |
| WO-2023046590-A1 | AN IMPROVED PHARMACEUTICAL COMPOSITION FOR NASAL USE, PREPARATION, AND USE THEREOF | JADRAN - GALENSKI LABORATORIJ D.D. (HR) | 2023-03-30 | — | — | WO | claimed |
| CN-112807278-B | Nasal composition and preparation method and application thereof | 湖北远大天天明制药有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-0082546-B2 | PHARMACEUTICAL MIXTURE AND METHOD FOR MAKING THE MIXTURE | FISONS plc (GB) | 1992-03-25 | — | — | EP | claimed |
| EP-0209547-B1 | DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS | RIKER LABORATORIES, INC. (US) | 1990-09-12 | — | — | EP | claimed |
| US-4814161-A | GLYCEROL PHOSPHATIDE | RIKER LABORATORIES, INC. (US) | 1989-03-21 | — | — | US | claimed |
| US-4741899-A | Process for arresting the proliferation of organisms that convert axillary secretions to malodorous materials | BRISTOL-MYERS COMPANY (US) | 1988-05-03 | — | — | US | claimed |
| EP-0209547-A1 | DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS. | RIKER LABORATORIES INC (US) | 1987-01-28 | — | — | EP | claimed |
| WO-1986004233-A1 | DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS | RIKER LABORATORIES, INC. (US) | 1986-07-31 | — | — | WO | claimed |
| US-4603131-A | Method and composition for treating and preventing irritation of the mucous membranes of the nose | BERNSTEIN, JOEL E. | 1986-07-29 | — | — | US | claimed |
| EP-0082546-B1 | PHARMACEUTICAL MIXTURE AND METHOD FOR MAKING THE MIXTURE | FISONS plc (GB) | 1985-08-14 | — | — | EP | claimed |
| EP-0093373-A1 | Method and composition for treating and preventing irritation of the mucous membranes of the nose | Bernstein, Joel E. (US) | 1983-11-09 | — | — | EP | claimed |
| EP-0082546-A1 | Pharmaceutical mixture and method for making the mixture | FISONS plc (GB) | 1983-06-29 | — | — | EP | claimed |